Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Besada

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 1, 2010
New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activitiesTamara Costas, Pedro Besada, Alessandro Piras, et al.
Current Topics in Medicinal Chemistry|April 14, 2004
Molecular recognition at purine and pyrimidine nucleotide (P2) receptorsKenneth A Jacobson, Stefano Costanzi, Michihiro Ohno, et al.
European Journal of Medicinal Chemistry|August 12, 2017
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitorsMaría Carmen Costas-Lago, Pedro Besada, Fernanda Rodríguez-Enríquez, et al.
Molecular Diversity|July 25, 2015
Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligandsLiane Saíz-Urra, Marta Teijeira, Virginia Rivero-Buceta, et al.
Novartis Foundation Symposium|June 30, 2006
Agonists and antagonists for P2 receptorsKenneth A Jacobson, Stefano Costanzi, Bhalchandra V Joshi, et al.
Biochemical Pharmacology|December 20, 2005
Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptorsKenneth A Jacobson, Stefano Costanzi, Andrei A Ivanov, et al.
Bioorganic Chemistry|August 9, 2021
Pyridazinones containing dithiocarbamoyl moieties as a new class of selective MAO-B inhibitorsPedro Besada, Dolores Viña, Tamara Costas, et al.
ACS Medicinal Chemistry Letters|March 18, 2022
Novel Pyridazin-3(2<i>H</i>)-one-Based Guanidine Derivatives as Potential DNA Minor Groove Binders with Anticancer ActivityMaría Carmen Costas-Lago, Noemí Vila, Adeyemi Rahman, et al.
Journal of Medicinal Chemistry|September 1, 2006
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptorPedro Besada, Dae Hong Shin, Stefano Costanzi, et al.
Biochemical Pharmacology|October 13, 2004
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptorMarco Cattaneo, Anna Lecchi, Michihiro Ohno, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|October 1, 2010
New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activitiesTamara Costas, Pedro Besada, Alessandro Piras, et al.
Current Topics in Medicinal Chemistry|April 14, 2004
Molecular recognition at purine and pyrimidine nucleotide (P2) receptorsKenneth A Jacobson, Stefano Costanzi, Michihiro Ohno, et al.
European Journal of Medicinal Chemistry|August 12, 2017
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitorsMaría Carmen Costas-Lago, Pedro Besada, Fernanda Rodríguez-Enríquez, et al.
Molecular Diversity|July 25, 2015
Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligandsLiane Saíz-Urra, Marta Teijeira, Virginia Rivero-Buceta, et al.
Novartis Foundation Symposium|June 30, 2006
Agonists and antagonists for P2 receptorsKenneth A Jacobson, Stefano Costanzi, Bhalchandra V Joshi, et al.
Biochemical Pharmacology|December 20, 2005
Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptorsKenneth A Jacobson, Stefano Costanzi, Andrei A Ivanov, et al.
Bioorganic Chemistry|August 9, 2021
Pyridazinones containing dithiocarbamoyl moieties as a new class of selective MAO-B inhibitorsPedro Besada, Dolores Viña, Tamara Costas, et al.
ACS Medicinal Chemistry Letters|March 18, 2022
Novel Pyridazin-3(2<i>H</i>)-one-Based Guanidine Derivatives as Potential DNA Minor Groove Binders with Anticancer ActivityMaría Carmen Costas-Lago, Noemí Vila, Adeyemi Rahman, et al.
Journal of Medicinal Chemistry|September 1, 2006
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptorPedro Besada, Dae Hong Shin, Stefano Costanzi, et al.
Biochemical Pharmacology|October 13, 2004
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptorMarco Cattaneo, Anna Lecchi, Michihiro Ohno, et al.
Pageof 4